Hartwig Medical Foundation welcomes new managing director

Hartwig Medical Foundation is pleased to announce that Robert Jan Lamers has joined the organization as its new managing director, effective September 1. He steps into the role after Hans van Snellenberg. Lamers’ arrival marks a new phase for Hartwig, as the organization evolves from a pioneer in DNA analysis into a leading innovator in data-driven, personalized cancer care.
At the interface of healthcare and data
Lamers has a background in biotechnology and over twenty years of experience leading innovative organizations at the crossroads of healthcare, data, and technology. He has previously headed several scale-ups and built a strong network within the (international) biotech- and healthcare sectors.
‘In Robert Jan Lamers we have found a new managing director who will build on the success of Hartwig Medical Foundation. With his leadership, we aim to accelerate progress even further and expand access for patients and physicians to precision diagnostics and personal treatments. He is a unifying leader with strategic vision who will guide Hartwig into its next phase of impact and growth.’ – Constantijn van Oranje, chair of the Supervisory Board of Hartwig Medical Foundation.

Driving greater impact
Lamers is eager to begin this new chapter with Hartwig Medical Foundation.
You read an article in the category Hartwig Medical Foundation. All news‘What appeals to me about Hartwig is the unique combination of patient focus, innovation, scientific depth, and societal impact. Together with dedicated partners and a strong team, we are committed to advancing cancer care. I look forward to meeting our partners and working together to achieve even greater impact for more patients.’ – Robert Jan Lamers
Also read
Arno de Quaasteniet new member of the board of Hartwig Medical Foundation
Hartwig Medical Foundation is pleased to announce that as of October 1, 2024, Arno de Quaasteniet (1977) has been appointed …
Hartwig visit to Jackson Laboratory in Farmington, CT
For interpretation of molecular results, Hartwig relies on the CKB resource that has been developed by The Jackson Laboratory, and …
Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing …
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.